Results 261 to 270 of about 98,806 (295)
Serum and Tissue Light-Chains as Disease Biomarkers in AL Amyloidosis. [PDF]
Int J Mol SciAimo A +12 more
europepmc +1 more source
New IDEAS Biorepository now available to researchers
Alzheimer's &Dementia, Volume 21, Issue 12, December 2025.
wiley +1 more source
Some of the next articles are maybe not open access.
Related searches:
Related searches:
Annual Review of Biochemistry, 1992
The biochemistry of amyloidosis as it relates to clinical medicine and experimental pathology is presented. Amyloidoses are complex disorders in which normally soluble precursors undergo pathological conformational changes and polymerize as insoluble fibrils with the beta-pleated sheet conformation.
Jean D. Sipe, A. S. Cohen
openaire +5 more sources
The biochemistry of amyloidosis as it relates to clinical medicine and experimental pathology is presented. Amyloidoses are complex disorders in which normally soluble precursors undergo pathological conformational changes and polymerize as insoluble fibrils with the beta-pleated sheet conformation.
Jean D. Sipe, A. S. Cohen
openaire +5 more sources
Hematology/Oncology Clinics of North America, 1999
Amyloidosis is considered rare but has an incidence similar to that of Hodgkin's disease and chronic granulocytic leukemia. The diagnosis should be considered in any patient with unexplained nephrotic-range proteinuria, heart failure, peripheral neuropathy, or hepatomegaly.
Dispenzieri, A, Lacy, MQ, Gertz, MA
openaire +3 more sources
Amyloidosis is considered rare but has an incidence similar to that of Hodgkin's disease and chronic granulocytic leukemia. The diagnosis should be considered in any patient with unexplained nephrotic-range proteinuria, heart failure, peripheral neuropathy, or hepatomegaly.
Dispenzieri, A, Lacy, MQ, Gertz, MA
openaire +3 more sources
Best Practice & Research Clinical Haematology, 2005
Amyloidosis is an uncommon plasma-cell dyscrasia with an incidence of eight patients per million per year. It is often difficult to recognize because of the myriad symptoms and vague nature of the clinical presentation. Symptoms include fatigue, dyspnea, edema, paresthesias, and weight loss.
Morie A, Gertz +3 more
openaire +2 more sources
Amyloidosis is an uncommon plasma-cell dyscrasia with an incidence of eight patients per million per year. It is often difficult to recognize because of the myriad symptoms and vague nature of the clinical presentation. Symptoms include fatigue, dyspnea, edema, paresthesias, and weight loss.
Morie A, Gertz +3 more
openaire +2 more sources
Current Opinion in Rheumatology, 1991
Amyloidosis is a disease involving the fibrillar deposition of proteins in a manner that uniformly leads to the presence of green birefringence on polarization microscopy after staining the involved tissues with Congo red. In the year summarized, a wide range of new information has accumulated about this disease.
A S, Cohen, L A, Jones
openaire +2 more sources
Amyloidosis is a disease involving the fibrillar deposition of proteins in a manner that uniformly leads to the presence of green birefringence on polarization microscopy after staining the involved tissues with Congo red. In the year summarized, a wide range of new information has accumulated about this disease.
A S, Cohen, L A, Jones
openaire +2 more sources
Current Opinion in Rheumatology, 1996
Developments concerning amyloidosis associated with rheumatic diseases or often causing musculoskeletal symptoms are reviewed. The pathogenesis, clinical manifestations, diagnosis, and therapy of amyloid A, amyloid light-chain, and amyloid beta 2-microglobulin amyloidosis are discussed from the standpoint of a clinical rheumatologist.
C, Friman, T, Pettersson
openaire +2 more sources
Developments concerning amyloidosis associated with rheumatic diseases or often causing musculoskeletal symptoms are reviewed. The pathogenesis, clinical manifestations, diagnosis, and therapy of amyloid A, amyloid light-chain, and amyloid beta 2-microglobulin amyloidosis are discussed from the standpoint of a clinical rheumatologist.
C, Friman, T, Pettersson
openaire +2 more sources
Journal of the American Podiatric Medical Association, 1990
The authors present a review of amyloidosis and its classification and clinical presentations. They also discuss its diagnosis and treatment, and present a case of amyloid deposition in the plantar weightbearing aspects of the feet, which exemplifies the classic clinical findings.
P K, Geistler, K G, Canter, N A, Staley
openaire +2 more sources
The authors present a review of amyloidosis and its classification and clinical presentations. They also discuss its diagnosis and treatment, and present a case of amyloid deposition in the plantar weightbearing aspects of the feet, which exemplifies the classic clinical findings.
P K, Geistler, K G, Canter, N A, Staley
openaire +2 more sources
Histopathology, 1994
Amyloidosis is a heterogeneous group of disorders characterized by extracellular deposition of abnormal protein fibrils which are dérived from different proteins in different forms of the disease. Asymptomatic amyloid deposition in a variety of tissues is a universal accompaniment of ageing, and clinical amyloidosis is not rare.
S Y, Tan, M B, Pepys
openaire +2 more sources
Amyloidosis is a heterogeneous group of disorders characterized by extracellular deposition of abnormal protein fibrils which are dérived from different proteins in different forms of the disease. Asymptomatic amyloid deposition in a variety of tissues is a universal accompaniment of ageing, and clinical amyloidosis is not rare.
S Y, Tan, M B, Pepys
openaire +2 more sources
Current Treatment Options in Oncology, 2006
Amyloidosis is a disease in which abnormal proteins form fibrillar tissue deposits that can compromise key viscera and lead to early death. In order to treat amyloidosis, the type of abnormal protein must be identified. The most common type is monoclonal immunoglobulin light chain or AL amyloidosis; the other important type is hereditary, caused by ...
openaire +4 more sources
Amyloidosis is a disease in which abnormal proteins form fibrillar tissue deposits that can compromise key viscera and lead to early death. In order to treat amyloidosis, the type of abnormal protein must be identified. The most common type is monoclonal immunoglobulin light chain or AL amyloidosis; the other important type is hereditary, caused by ...
openaire +4 more sources